NewsAI-assisted

Kane Biotech Secures Global Distribution Deal for XSONX’s Wound Hygiene System

Kane Biotech to distribute XSONX's Wound Hygiene System in Canada, Australia, NZ, and GCC.

Simantini Singh Deo
By Simantini Singh Deo
Senior Content Writer
Oct 18, 2024Updated Jun 26, 2025 · 2 min read
Share
Kane Biotech Secures Global Distribution Deal for XSONX’s Wound Hygiene System
https://www.linkedin.com/pulse/transforming-wound-treatment-xsonx-hygiene-system-fairley-mba-63iue/
AI-assisted reporting
Reviewed by Simantini Singh Deo, Senior Content Writer

Kane Biotech Inc. has announced an upscale five-year distribution agreement with XSONX LLC, granting Kane the rights to distribute XSONX's Wound Hygiene System in Canada, Australia, New Zealand, and the Gulf Cooperation Council (GCC) countries. 


“The XSONX Wound Hygiene System is a proven contributor to chronic wound healing and will nicely complement Kane’s revyve™ product line. I’m excited about this opportunity to partner with XSONX and to make their debridement tool widely available to wound care professionals via our distribution network,” said Marc Edwards, President & CEO of Kane Biotech.


The Wound Hygiene System is a cordless tool that uses vibrations to clean and debride chronic and contaminated wounds safely. Kane will introduce this system to Canadian healthcare professionals at the Wounds Canada National Hybrid Conference alongside its revyve™, an antimicrobial wound gel and spray product. 


Dr. Wade Farrow, founder and CEO of XSONX, mentioned, “According to recently released consensus documents, 60% of wounds in the US are under-debrided. This may be even higher in Canada and other international markets, making XSONX an important tool for practitioners. Kane’s dedication to quality and its growing international distribution network makes them our ideal partner.

TopicsNews
Simantini Singh Deo
Written by
Simantini Singh Deo
Senior Content Writer

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Loading discussion…

More from Pharma News

All stories →